Eli Casdin

Eli Casdin has an estimated net worth of $5.76 Billion. This is based on reported shares across multiple companies, which include SomaLogic, Inc., GeneDx Holdings Corp., EQRx, Inc., CONSTELLATION PHARMACEUTICALS INC, Fulcrum Therapeutics, Inc., BIOLIFE SOLUTIONS INC, MAXCYTE, INC., STANDARD BIOTOOLS INC., 2seventy bio, Inc., Generation Bio Co., Tenaya Therapeutics, Inc., EXACT SCIENCES CORP, Absci Corp, and Century Therapeutics, Inc..

2024 was Eli Casdin's most active year for acquiring shares with 61 total transactions. Eli Casdin's most active month to acquire stocks was the month of April. 2024 was Eli Casdin's most active year for disposing of shares, totalling 16 transactions. Eli Casdin's most active month to dispose stocks was the month of December. 2024 saw Eli Casdin paying a total of $177,455,450.96 for 85,767,639 shares, this is the most they've acquired in one year. In 2025 Eli Casdin cashed out on 5,888,923 shares for a total of $139,855,825.00, their largest year based on trade value.